6-ethylthieno<2,3-b>pyridine | 28988-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 6-ethylthieno<2,3-b>pyridine
• 英文别名: 6-Ethylthieno[2,3-b]pyridine
• CAS: 28988-18-3
• 化学式: C₉H₉NS
• 分子量: 163.243
• InChiKey: GYDCBWNQUYRNKG-UHFFFAOYSA-N

反应信息

• 作为产物：
  描述：

  1-戊烯-3-酮 、 bis(2-thienylammonium)hexachlorostannate(IV) 以 乙醇 为溶剂， 以45%的产率得到4-乙基噻吩并[2,3-b]吡啶
  参考文献：
  名称：

  Klemm, L. H.; Shabtai, J.; Michaud, Joan, Journal of Heterocyclic Chemistry, 1981, vol. 18, p. 1383 - 1387

  摘要：

  DOI：

文献信息

• BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
  申请人：AC Immune SA

  公开号：EP4001277A2

  公开（公告）日：2022-05-25

  The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

  本发明涉及可用于诊断、监测疾病进展或监测药物活性的新型化合物，这些疾病和异常与α-突触核蛋白（a-synuclein，A-synuclein，aSynuclein，A-syn，α-syn，aSyn）聚集有关，包括但不限于路易体和/或路易神经元，如帕金森病。本化合物尤其适用于确定此类疾病的易感性、监测残余疾病或预测患有此类疾病的患者对某种药物治疗的反应性。本化合物还可用于治疗、缓解或预防与α-突触核蛋白聚集相关的失调或异常。
• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20190290771A1

  公开（公告）日：2019-09-26

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.